Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2025)

Xeris Biopharma Holdings' FCF Margin history spans 6 years, with the latest figure at 23.36% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 2007.0% year-over-year to 23.36%, compared with a TTM value of 9.81% through Dec 2025, up 2802.0%, and an annual FY2025 reading of 9.81%, up 2802.0% over the prior year.
  • FCF Margin for Q4 2025 was 23.36% at Xeris Biopharma Holdings, down from 24.78% in the prior quarter.
  • The five-year high for FCF Margin was 24.78% in Q3 2025, with the low at 292.32% in Q1 2021.
  • Average FCF Margin over 5 years is 72.32%, with a median of 42.4% recorded in 2023.
  • Year-over-year, FCF Margin soared 14471bps in 2022 and then tumbled -1354bps in 2024.
  • Tracing XERS's FCF Margin over 5 years: stood at 135.69% in 2021, then soared by 64bps to 48.63% in 2022, then skyrocketed by 135bps to 16.83% in 2023, then crashed by -80bps to 3.29% in 2024, then soared by 611bps to 23.36% in 2025.
  • Per Business Quant, the three most recent readings for XERS's FCF Margin are 23.36% (Q4 2025), 24.78% (Q3 2025), and 0.25% (Q2 2025).